stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Return on assets
Neurocrine Biosciences, Inc.'s return on assets over the twelve months to 30 September 2026 was 14.2%, up 2.7 percentage points from fiscal 2025 (11.5%). Over the past ten years it has ranged from −33.6% (fiscal 2016) to 26.8% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 11.5% | 1.67 |
| FY2024 | 9.79% | 0.90 |
| FY2023 | 8.89% | 1.93 |
| FY2022 | 6.96% | 2.25 |
| FY2021 | 4.71% | (22.08) |
| FY2020 | 26.8% | 23.57 |
| FY2019 | 3.22% | 0.89 |
| FY2018 | 2.33% | 26.43 |
| FY2017 | −24.1% | 9.50 |
| FY2016 | −33.6% | (8.82) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ZTS Zoetis Inc. compare | 17.8% |
| UTHR United Therapeutics Corporation compare | 17.1% |
| NBIX Neurocrine Biosciences, Inc. | 14.2% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 12.9% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.44% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ALKS Alkermes plc compare | −0.01% |
| ELAN Elanco Animal Health Incorporated compare | −1.46% |
| VTRS Viatris Inc. compare | −1.67% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement